Skip to main content

Table 7 Current clinical trials of HDACis as a combination therapy in GBM

From: The application of histone deacetylases inhibitors in glioblastoma

HDACis

synergistic members

conditions

phase

trial identifier

reference

Vorinostat (SAHA)

Bevacizumab

Recurrent GBM

phase II

NCT01738646

[213]

Bevacizumab, Temozolomide

Recurrent Malignant Gliomas

phase I/II

NCT00939991

[214]

Temozolomide

Malignant Gliomas

phase I

NCT00268385

[215]

Radiation

Recurrent Glioma

phase I

NCT01378481

-

Isotretinoin, Temozolomide

Recurrent GBM

phase I/II

NCT00555399

-

Erlotinib, Temozolomide

Recurrent GBM

phase I/II

NCT01110876

-

Temozolomide, Radiation

Newly Diagnosed GBM

phase I/II

NCT00731731

[216]

Pembrolizumab, Temozolomide

Newly Diagnosed GBM

phase I

NCT03426891

-

Bortezomib

Recurrent GBM

phase II

NCT00641706

[217]

Bevacizumab, Irinotecan

Recurrent GBM

phase I

NCT00762255

[218]

Panobinostat (LBH-589)

Bevacizumab

Recurrent High Grade Glioma

phase I/II

NCT00859222

[219]

Radiation

Recurrent Glioma

phase I

NCT01324635

-

Valproate (valproic acid, VPA)

Sorafenib Tosylate, Sildenafil Citrate

Recurrent High-Grade Glioma

phase II

NCT01817751

-

Temozolomide, Radiation

High Grade Gliomas

phase II

NCT00302159

[220,221,222]

Nivolumab, Radiation

Recurrent GBM

phase I

NCT02648633

-

Belinostat (PXD101)

Temozolomide, Radiation

GBM

phase II

NCT02137759

-